Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT

This study aimed to compare very late vascular response after stent implantation between everolimus-eluting stent (EES) with a thin, non-adhesive, durable, biocompatible fluorinated polymer and biolimus-eluting stent (BES) with a biodegradable polymer by optical coherence tomography (OCT). In the NO...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology 2017-12, Vol.70 (6), p.530-536
Main Authors: Katayama, Yosuke, Kubo, Takashi, Akasaka, Takashi, Ino, Yasushi, Kimura, Kazuo, Okura, Hiroyuki, Shinke, Toshiro, Igarashi, Keiichi, Kadota, Kazushige, Kozuma, Ken, Tanabe, Kengo, Nakagawa, Yoshihisa, Muramatsu, Toshiya, Morino, Yoshihiro, Kimura, Takeshi
Format: Article
Language:English
Subjects:
Aged
Biocompatible Materials - administration & dosage
Biocompatible Materials - therapeutic use
Coronary Vessels - pathology
Drug-eluting stents
Drug-Eluting Stents - adverse effects
Everolimus - administration & dosage
Everolimus - therapeutic use
Female
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - therapeutic use
Male
Middle Aged
Neointima - pathology
Optical coherence tomography
Percutaneous Coronary Intervention
Polymers - administration & dosage
Polymers - therapeutic use
Sirolimus - administration & dosage
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Tomography, Optical Coherence - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to compare very late vascular response after stent implantation between everolimus-eluting stent (EES) with a thin, non-adhesive, durable, biocompatible fluorinated polymer and biolimus-eluting stent (BES) with a biodegradable polymer by optical coherence tomography (OCT). In the NOBORI-BES Versus XIENCE V/PROMUS-EES Trial (NEXT), a formal OCT substudy investigated 48 patients (27 EES-treated lesions in 23 patients and 28 BES-treated lesions in 25 patients) with 2-year (18–30 months) follow-up imaging at 18 centers. The percentage of uncovered strut by neointima was significantly lower in EES compared with BES (2.1±4.7% vs. 7.9±10.8%, p=0.013). The percentage of malapposed strut was not different between EES and BES (0.1±0.3% vs. 0.5±1.3%, p=0.138). The frequency of stent with evagination, which is identified as outward bulges in the luminal contour between struts, was significantly lower in EES compared with BES (22% vs. 86%, p
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2017.04.005